TrialHaematologica2015

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Philippe Moreau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.